TITAN SPINE ANNOUNCES THE FIRST ENDOSKELETON® INTERBODY FUSION CASES IN AUSTRALIA Surgeries open entry into new market and expand global footprint
MEQUON, Wis., November 16, 2017 – Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced the first surgeries in Australia using the Company’s proprietary Endoskeleton® interbody fusion devices and surface technology, marking the Company’s entry into a robust new market. The first two ALIF cases were performed successfully in October by Dr. Richard Laherty, MBBS FRACS CIME, spine surgeon at Queensland Neurosurgery and Spine Surgery at the Princess Alexandra Hospital near Brisbane.
Dr. Laherty commented, “I have been keeping up on the wealth of studies Titan Spine has published on their proprietary surface technologies over the years that have consistently shown the ability to create a superior osteogenic environment over other materials and surfaces. I was pleased to finally have the opportunity to use the Endoskeleton®.
Titan Spine received registration approval from the Australian Therapeutic Goods Administration (TGA) in June 2014 to commercially market its full line of Endoskeleton® .
Kevin Gemas, President of Titan Spine, added, “Over the past few years we have focused our attention primarily in the U.S. and portions of the EU to educate on and demonstrate the value of our titanium devices featuring our differentiated surface technology. After securing the CMS new technology ICD-10 code, expanding our U.S. sales force, and achieving strong domestic revenue acceleration, we are also now focusing on select OUS markets, such as Australia, that we feel can add to our top and bottom lines. We anticipate tremendous growth in this new region to drive substantial growth for Titan in the coming quarters and beyond.”
Titan Spine offers a full line of Endoskeleton®1,2,3 All Endoskeleton® warranty.
About Titan Spine
Titan Spine, LLC is a surface technology company focused on the design and manufacture of unique interbody fusion devices for the spine. The company is committed to advancing the science of surface engineering to enhance the treatment of various pathologies of the spine that require fusion. Titan Spine, located in Mequon, Wisconsin and Laichingen, Germany, markets a full line of Endoskeleton® www.titanspine.com.
1 Olivares-Navarrete, R., Hyzy, S.L., Slosar, P.J., Schneider, J.M., Schwartz, Z., and Boyan, B.D. (2015). Implant materials generate different peri-implant inflammatory factors: PEEK promotes fibrosis and micro-textured titanium promotes osteogenic factors. Spine, Volume 40, Issue 6, 399–404.2 Olivares-Navarrete, R., Gittens, R.A., Schneider, J.M., Hyzy, S.L., Haithcock, D.A., Ullrich, P.F., Schwartz, Z., Boyan, B.D. (2012). Osteoblasts exhibit a more differentiated phenotype and increased bone morphogenetic production on titanium alloy substrates than poly-ether-ether-ketone. The Spine Journal, 12, 265-272.3 Olivares-Navarrete, R., Hyzy, S.L., Gittens, R.A., Schneider, J.M., Haithcock, D.A., Ullrich, P.F., Slosar, P. J., Schwartz, Z., Boyan, B.D. (2013). Rough titanium alloys regulate osteoblast production of angiogenic factors. The Spine Journal, 13, 1563-1570.
# # #